Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002973 · ClinicalTrials.gov registry record · Phase 2
Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00002973 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 34 participants.
The verdict
NCT00002973, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan and whole-body hyperthermia in treating patients with advanced melanoma.
Interventions
- DRUG melphalan
- PROCEDURE hyperthermia treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1995-12 |
| Est. Completion | 2000-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002973
The ClinicalTrials.gov registry entry for NCT00002973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00002973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002973 about?
NCT00002973 is a clinical study titled "Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor cells. PURPOSE: Phas...
What is the current status of trial NCT00002973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 1995-12. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00002973?
The interventions under investigation include: melphalan (DRUG), hyperthermia treatment (PROCEDURE).
Who is sponsoring clinical trial NCT00002973?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.